The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, ...

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 — but only if between two and ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

Lenacapavir, a once-a-year injection, can treat HIV, prevent transmission and stop new infections — all with a single shot.

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

Wesley Sundquist, a biochemist at the University of Utah, was recently featured in Time's annual "100 Most Influential People ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating lenacapavir, a long-lasting HIV prevention and treatment drug.

The late night host made the president an offer he's certain to refuse.